A
Ayako Mikami
Publications - 5
Citations - 238
Ayako Mikami is an academic researcher. The author has contributed to research in topics: Clinical trial & Interquartile range. The author has an hindex of 3, co-authored 5 publications receiving 60 citations.
Papers
More filters
Journal ArticleDOI
Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN.
Nobuaki Matsunaga,Kayoko Hayakawa,Mari Terada,Hiroshi Ohtsu,Yusuke Asai,Shinya Tsuzuki,Setsuko Suzuki,Ako Toyoda,Kumiko Suzuki,Mio Endo,Naoki Fujii,Michiyo Suzuki,Sho Saito,Yukari Uemura,Taro Shibata,Masashi Kondo,Kazuo Izumi,Junko Terada-Hirashima,Ayako Mikami,Wataru Sugiura,Norio Ohmagari +20 more
TL;DR: The clinical epidemiological features of COVID-19 in hospitalized patients in Japan demonstrated fewer comorbidities and a trend towards lower mortality when compared with existing inpatient studies in other countries.
Journal ArticleDOI
Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: In this article, the authors examined the effect of BNT162b2-elicited SARS-CoV-2 neutralizing activity (50% neutralization titer: NT50; assessed using infectious virions) with various determinants and the potency of sera against variants of concerns.
Journal ArticleDOI
Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan
TL;DR: A search for ongoing clinical trials for the treatment of COVID-19 at the clinicaltrials.gov database found 48 trials, and of these, 41 trials adopted drug intervention and the other 7 trials utilized biological intervention.
Journal ArticleDOI
Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial
Junko Terada-Hirashima,Manabu Suzuki,Yukari Uemura,Masayuki Hojo,Ayako Mikami,Wataru Sugiura,Norio Ohmagari,Haruhito Sugiyama +7 more
TL;DR: If the hypotheses that pneumonia exacerbation rate reduction is more significant in the cicleonide treatment group than in the symptomatic treatment group and that ciclesonide is safe for use are valid, cicles onide (Alvesco R) will serve as an important therapeutic option for COVID-19 patients.
Posted ContentDOI
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
Kenji Maeda,Masayuki Amano,Yukari Uemura,Kiyoto Tsuchiya,Tomoko Matsushima,Kenta Noda,Yosuke Shimizu,Asuka Fujiwara,Yuki Takamatsu,Yasuko Ichikawa,Hidehiro Nishimura,Mari Kinoshita,Shota Matsumoto,Hiroyuki Gatanaga,Kazuhisa Yoshimura,Shinichi Oka,Ayako Mikami,Wataru Sugiura,Toshiyuki Sato,Tomokazu Yoshida,Shinya Shimada,Hiroaki Mitsuya,Hiroaki Mitsuya +22 more
TL;DR: Since BNT162b2-elicited immunity against SARS-CoV-2 is short, an additional vaccine or other protective measures are needed.